One of the most credible breast-cancer patient-advocacy groups has come out with a negative opinion about the use of the drug Avastin for women who have never consumed it earlier saying that it increases the rate of fatal side effects by almost 50%.

It was followed by U. S. Food and Drug Administration being doubtful about drug's effectiveness.

In December, FDA issued this statement that they were against the approval of this drug. The maker of Avastin, Roche Holding AG unit Genentech, came out with a protesting statement that this drug is the most suitable option for women with breast cancer in the current scenario and the firm was quite sure about its continuance in the market.

Elizabeth Thompson, president of the Komen group, made this thing quite clear during an interview that they are not going to change their position but at the same time it has been reported that there have been many cases where women describe that how this drug saved their lives when they had given up on chemotherapy.

According to a recent research published in the Journal of the American Medical Association, around 2.5% of cancer patients, who mixes this drug with chemotherapy, die out of the treatment whereas only 1.7% of cancer patients die if they opt only for conventional chemo.